Swedish Orphan Biovitrum AB

Type: Company
Name: Swedish Orphan Biovitrum AB (Biovitrum AB)
Nationality: Sweden
Web Address: http://www.biovitrum.com/
Fact Sheet: Fact Sheet for Biovitrum AB
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Hanover appoints new European head of healthcare

:13 in Marketing Services Hanover has announced the return of Emma Eatwell to the agency, taking over the role of European healthcare head. Ms Eatwell originally Hanover last year to become head of public policy and advocacy at Swedish Orphan Biovitrum, ... [Published Zenopa - Oct 23 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

Emma Eatwell returns to Hanover

Hanover reappoints Emma Eatwell to head its Brussels Healthcare Business.She will advise Hanover’s healthcare clients on corporate and brand agendas in Brussels, and on market and patient access campaigns across Europe.Emma left the company in April 2013, ... [Published GorkanaPR - Oct 21 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 2 reports

BioSpecifics Technologies Corp. Announces Presentation of Encouraging Preclinical Data for CCH from Collaborative Uterine Fibroid Study with Duke Medicine

LYNBROOK, N.Y. , Oct. 16, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. ( NASDAQ: BSTC ), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX ® (collagenase clostridium histolyticum or CCH) in the ... [Published Fat Pitch Financials - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Invitation - Presentation of Sobi's third quarter results 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the third quarter 2014. Financial analysts and media are invited to participate in a telephone conference, which will ... ... [Published Yahoo! Finance UK and Ireland - Oct 16 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Invitation - Presentation of Sobi''s third quarter results 2014

Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the third quarter 2014.Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 13:00 CET (08:00 EST). ... [Published Nasdaq - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 2 reports

Pharming and Swedish Orphan Biovitrum amends and extends Ruconest distribution agreement in Austria, Germany and Netherlands

Biotech company Pharming Group NV (Amsterdam:PHARM.AS) reported on Monday the amendment and extension of the Ruconest distribution agreement with Swedish Orphan Biovitrum AB (publ) (SS:SOBI).With immediate effect, Pharming will focus on Ruconest's direct ... [Published Individual.com - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 5 reports

Pharming and Sobi amend and extend Ruconest distribution agreement

Pharming Group NV and Swedish Orphan Biovitrum AB, or Sobi, has announced the amendment and extension of the Ruconest distribution agreement between Pharming and Sobi. Effective immediately, Pharming will focus on direct commercialization in Austria, ... [Published Individual.com - Oct 13 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 2 reports

Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe

, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.For more information please contact:Media relations Investor relatio ... [Published ACN Newswire - Oct 09 2014]
First reported Sep 24 2014 - Updated Sep 24 2014 - 1 reports

Sobi opens new office in Waltham, Massachusetts

Swedish Orphan Biovitrum AB, or Sobi, a biotechnology company, has opened its new North American office in Waltham, Massachusetts. "North America is an increasingly important region for Sobi, and building our team in the Boston area supports us in our ... [Published Individual.com - Sep 24 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 2 reports

Biogen Idec Offers Growth Investors An Attractive Entry Point

By BMD Asset Management and Research :Biogen Idec BIIB reported strong second quarter earnings on July 23rd, causing analysts to revise their estimates considerably higher for both this year and next year. While the stock price has risen over 8% since ... [Published BioPortfolio - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 2 reports

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has added the preclinical fusion molecule rFVIIIFc-XTEN-vWF for hemophilia to its collaboration with US biotech firm Biogen Idec (Nasdaq: BIIB). The technology is proprietary to Amunix Operating, ... [Published Pharma Letter - Sep 19 2014]
First reported Jun 25 2014 - Updated Jun 26 2014 - 3 reports

Sobi seeks EMA approval for Xiapex for Peyronies disease

Swedish Orphan Biovitrum (Sobi) has filed for an extension of the label for Xiapex with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. ... [Published PBR - News - Jun 26 2014]

Quotes

...Christian Hierholzer, managing director at Hanover Brussels, said: "Her excellent understanding of the policy and regulatory environments across Europe will be a key asset in enabling us to continue to provide clients with clear, strategic advice to achieve their business goals." This comes after the agency appointed Richard Sloggett, formerly of MHP Health, as a new associate director earlier this year
...it is estimated that 35 to 40 percent of Dupuytren's surgeries treat more than one cord," commented Thomas L Wegman , President of BioSpecifics. "In addition to growth from the expanded label, we also look forward to broadening the commercial reach of XIAFLEX into markets outside the U S with the potential approval in Japan for Dupuytren's contracture and in the EU for Peyronie's disease. With all of these avenues to reach new patients with XIAFLEX, we expect to see continued commercial success through 2015."
...products marketed as XIAFLEX ® (collagenase clostridium histolyticum or CCH) in the U S and XIAPEX ® in the EU, announces that a paper titled, "Stiffness of Human Uterine Fibroids is Reduced After Treatment with Purified Clostridial Collagenase due to Collagen Degradation" was presented at the Mechanotransduction in the Reproductive Tract conference hosted by the Campion Fund of the Phyllis and Mark Leppert Foundation for...
Invitation - Presentation of Sobi "s third quarter results 2014"

More Content

All (60) | News (36) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (2) | Press Releases (14)
sort by: Date | Relevance
Hanover appoints new European head of healthcare [Published Zenopa - Oct 23 2014]
Emma Eatwell returns to Hanover [Published PMLive - Oct 23 2014]
Emma Eatwell returns to Hanover [Published GorkanaPR - Oct 21 2014]
BioSpecifics Technologies Corp. Announces FDA A... [Published Myrtle Beach Sun News - Oct 21 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Fat Pitch Financials - Oct 16 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published Stock Nod - Oct 16 2014]
Invitation - Presentation of Sobi's third quart... [Published Yahoo! Finance UK and Ireland - Oct 16 2014]
Invitation - Presentation of Sobi''s third quar... [Published Nasdaq - Oct 16 2014]
Biotech bucks macro uncertainties - strong quar... [Published Nasdaq - Oct 16 2014]
Pharming and Swedish Orphan Biovitrum amends an... [Published Individual.com - Oct 14 2014]
PHARMING : PHARM: Optimizing Ruconest Distribut... [Published 4 Traders - Oct 14 2014]
Pharming and Sobi amend and extend Ruconest dis... [Published Individual.com - Oct 13 2014]
SOBI and Pharming extend and amend Ruconest agr... [Published Pharma Letter - Oct 13 2014]
BRIEF-Pharming and SOBI extend distribution agr... [Published Reuters - Oct 13 2014]
Pharming and Swedish Orphan Biovitrum Amend and... [Published ADVFN UK - Oct 13 2014]
Pharming and Swedish Orphan Biovitrum Amend and... [Published 4 Traders - Oct 13 2014]
Sobi's collaboration partner Biogen Idec files ... [Published ACN Newswire - Oct 09 2014]
Sobi’s collaboration partner Biogen Idec files ... [Published MyNewsDesk - Oct 09 2014]
BioSpecifics Technologies Corp. Announces Sudde... [Published Town Hall - Oct 08 2014]
Sobi opens new office in Waltham, Massachusetts [Published Individual.com - Sep 24 2014]
Sobi opens North American operations [Published ACN Newswire - Sep 22 2014]
Biogen Idec Offers Growth Investors An Attracti... [Published BioPortfolio - Sep 22 2014]
Biogen Idec Offers Growth Investors An Attracti... [Published Seeking Alpha - Sep 22 2014]
BioSpecifics Technologies : to Present at the 2... [Published 4 Traders - Sep 19 2014]
Swedish Orphan Biovitrum adds new molecule to i... [Published Pharma Letter - Sep 19 2014]
Sobi expands Haemophilia development portfolio ... [Published GlobeNewswire: Acquisitions News - Sep 19 2014]
REG-Sobi expands Haemophilia development portfo... [Published Reuters - Sep 19 2014]
New number of shares and votes in Swedish Orpha... [Published GlobeNewswire: Advertising News - Jul 31 2014]
Sobi's board of directors exercises authorisati... [Published GlobeNewswire: Acquisitions News - Jul 18 2014]
Sobi awarded Company of the Year at the Europea... [Published GlobeNewswire: Acquisitions News - Jul 01 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Sobi seeks EMA approval for Xiapex for Peyronie... [Published PBR - News - Jun 26 2014]
Swedish Orphan Biovitrum (Sobi) has filed for an extension of the label for Xiapex with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. ...
BioSpecifics Technologies Corp. Announces Filin... [Published PR Newswire: Health - Jun 25 2014]
LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, announced today that ...
Sobi files for EU approval of Xiapex for Peyron... [Published PR Newswire: Financial Services - Jun 25 2014]
STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) ...
ORFADIN (Nitisinone) Capsule [SWEDISH ORPHAN BI... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Updated Date: Jun 11, 2014 EST ...
Biogen, Sobi pledge hemophilia drug donation in... [Published Yahoo! Health News - May 12 2014]
Biogen Idec Inc and partner Swedish Orphan Biovitrum AB on Monday said they will donate hemophilia drugs for use in developing nations in quantities large enough to treat tens of thousands of patients over the next decade. The potentially life-sa... ...
1 2

Press Releases

sort by: Date | Relevance
Sobi expands Haemophilia development portfolio ... [Published GlobeNewswire: Acquisitions News - Sep 19 2014]
New number of shares and votes in Swedish Orpha... [Published GlobeNewswire: Advertising News - Jul 31 2014]
Sobi's board of directors exercises authorisati... [Published GlobeNewswire: Acquisitions News - Jul 18 2014]
Sobi awarded Company of the Year at the Europea... [Published GlobeNewswire: Acquisitions News - Jul 01 2014]
Sobi files for EU approval of Xiapex for Peyron... [Published GlobeNewswire: Advertising News - Jun 25 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.